Navigation Links
PPD Names VPs for North America and Asia
Date:10/10/2007

Expands global senior leadership team; restructures business units

geographically

WILMINGTON, N.C., Oct. 10 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the appointments of Paul D. Colvin as senior vice president of clinical operations for North America and Simon J. Britton as vice president of clinical operations for Asia.

Mr. Colvin joins PPD from Eli Lilly and Company where he most recently directed clinical operations and global patient enrollment optimization. During his 14-year career at Lilly, he held a series of leadership positions including chief operations officer for the global cardiovascular brand team; European clinical operations senior manager for the oncology, critical care, primary care and neuroscience business units; global clinical operations manager for oncology project teams; and clinical project management leader for the oncology project team.

"Paul Colvin brings extensive global development experience across a wide range of therapeutic areas garnered during an impressive tenure with Lilly," said William Sharbaugh, chief operating officer of PPD. "His experience as a leader in the trenches of clinical drug development will serve him well in overseeing our North American Phase II-IV operational unit."

The position assumed by Mr. Britton is a new senior management role created specifically for the company's business on that continent.

"With Asia's escalating importance to global drug development, additional leadership will enable us to drive PPD's continued growth in the region," Mr. Sharbaugh said. "We are pleased to gain Simon Britton as a member of our team with his comprehensive international experience and proven ability to expand business scope and deliver quality results."

Mr. Britton spent the last seven years at GlaxoSmithKline where he most recently served as head of international clinical operations, managing the company's global clinical operations group across 25 countries. He brings more than 16 years' experience in leadership roles in the biopharmaceutical industry.

With Mr. Britton's appointment, PPD has divided its Phase II-IV operational units into four distinct territories: North America; Latin America; Europe, Middle East and Africa (EMEA); and Asia.

"This strategic restructuring of our business units geographically will enhance our ability to leverage PPD talent globally, strengthen internal standardization of our processes and further our ability to manage complex multinational trials efficiently," Mr. Sharbaugh added.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 29 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employees' performance and value to PPD as well as the geographic restructuring, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; success in sales growth; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Louise Caudle

+919 456 4467

louise.caudle@rtp.ppdi.com

Analysts/Investors:

Steve Smith

+910 558 7585

stephen.smith@wilm.ppdi.com


'/>"/>
SOURCE PPD, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
4. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
5. Health Minister Wants Names of Uncooperative Hospital Consultants
6. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
7. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
8. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
9. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
10. Rise In Obesity Among North Qeenslanders
11. Northfield Labs Receives FDA Comments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology: